SCHEMBL6485735

SCHEMBL6485735

C=CCC(COC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)COC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 4/20 0.51
CTSL P07711 4/20 0.51
CTSK P43235 3/20 0.51
CTSS P25774 3/20 0.51
CASP3 P42574 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ELANE P08246 2/20 0.47
PRTN3 P24158 1/20 0.47
ATM Q13315 1/20 0.46
CA2 P00918 1/20 0.46
CA5A P35218 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
CASP6 P55212 1/20 0.46
CASP8 Q14790 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3740016 0.94 CTSB (0.48) CTSBCTSLCTSKCTSSCASP3
SCHEMBL3737072 0.89 MBOAT4 (0.45) CTSBCTSLCTSKCTSSCASP3
SCHEMBL6474938 0.84 CASP3 (0.56) CTSBCTSLCTSKCTSSCASP3
SCHEMBL24556965 0.84 CTSK (0.58) CTSBCTSLCTSKCTSSCASP3
SCHEMBL7940778 0.83 CTSB (0.64) CTSBCTSLCTSKCTSSCASP3
SCHEMBL3732500 0.83 CTSL (0.57) CTSBCTSLCTSKCTSSCASP3
SCHEMBL3731639 0.82 CTSB (0.56) CTSBCTSLCTSKCTSSCASP3
SCHEMBL6650211 0.81 CTSK (0.58) CTSBCTSLCTSKCTSSCASP3
SCHEMBL3733697 0.81 CTSB (0.53) CTSBCTSLCTSKCTSSCASP3
SCHEMBL7600088 0.81 CTSB (0.53) CTSBCTSLCTSKCTSSCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974802-B2 Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine MEDIVIR AB (SE) 2005-12-13 US disclosed
US-6458772-B1 Prodrugs MEDIVIR AB (SE) 2002-10-01 US disclosed
US-20020128301-A1 Non-nucleoside reverse transcriptase inhibitors AB, Medivir (SE) 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128301-A1 Non-nucleoside reverse transcriptase inhibitors SUB1, CBR1, GAR1 CTSB 3486/4885CTSL 1476/4885CTSK 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.